Drug development firm Evotec has signed an extension to its discovery chemistry agreement, started in May, with Oxford-based Avidex which is developing treatments for cancer.
Drug development firm Evotec has signed an extension to its discovery chemistry agreement, started in May, with Oxford-based Avidex which is developing treatments for cancer.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article